AAV gene therapy has crossed into commercial reality, and its patent landscape is distinctive because an AAV therapy is a modular product whose parts are patented separately. An adeno-associated virus vector delivers a therapeutic gene by packaging it inside an engineered protein shell, the capsid, whose surface engages target-cell receptors and whose fate through endocytosis, endosomal escape, and nuclear import determines where the therapy goes and how the immune system responds to it.¹ The intellectual property divides across distinct regions, each a distinct area of patenting: the capsid, spanning natural serotypes and, increasingly, engineered capsids produced by directed evolution, structure-guided design, and machine-learning-guided design;²,³,⁴,⁵ the strategies that address immunogenicity, because pre-existing neutralizing antibodies exclude many patients and the immune response generally prevents redosing;⁶,⁷ the transgene expression cassette, including the promoter and regulatory elements that control where and how strongly the gene is expressed; and the manufacturing process, where empty-capsid content, host-cell productivity, and the ratio of full to empty particles remain challenges at commercial scale.⁸ Because a therapy depends on several of these layers and they are often held by different owners, freedom-to-operate for an AAV product is a multi-layer, multi-owner analysis rather than a single clearance.

The competitive and legal environment has raised the stakes across every layer. Capsid engineering is the most active area of IP, with specialized platform companies developing next-generation capsids that target specific tissues such as the brain, muscle, and retina and that aim to evade pre-existing immunity, and licensing these platforms to larger developers.⁴,⁹ At the same time, foundational vector patents have been litigated, with the Federal Circuit deciding an appeal on core AAV vector claims in early 2026, so the boundaries of the foundational estate continue to be tested even as the field advances.¹⁰ The commercial ground is set by a broader wave of approved products: as of the 2024 review window, the US Food and Drug Administration had approved fourteen cellular and gene therapy products across the modality, of which the AAV-based Luxturna (voretigene neparvovec-rzyl) for RPE65-mediated inherited retinal dystrophy remains the AAV exemplar, first approved in the United States in 2017 and separately authorized in the European Union.⁴,¹¹,¹² Because applications publish about eighteen months after filing, the newest capsid and immune-evasion filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

The strategic question is where defensible, hard-to-design-around IP sits. Across the Cypris corpus of more than 500 million patents and scientific papers, the AAV capsid-variant set holds on the order of 12,966 families and grew from about 828 in 2020 to roughly 1,818 in 2024, with the most active assignees led by the University of Pennsylvania, Voyager Therapeutics, the University of Massachusetts, Genzyme, and UC San Diego, and the United States far ahead of China, France, and the United Kingdom on geography; 2025 and 2026 counts are partial because of the publication lag. The most active and high-value ground is in engineered capsids that both target a tissue precisely and evade pre-existing immunity, because these directly address the field's central limitations, and receptor-guided and machine-learning-guided capsid design are advancing quickly here.²,³,⁴,⁵ Redosing and immune-modulation technologies are a distinct and comparatively open layer,⁶,⁷ as are manufacturing methods that raise the full-to-empty ratio and lower cost,⁸ and expression-cassette designs that improve durability and tissue specificity.⁴,⁹ Reading the landscape by layer and by owner, and tracking both the patents and the underlying virology and immunology research, is what separates a workable position from a blocked one.

What creates FTO risk in AAV gene therapy

Capsid claims. These cover natural serotypes and engineered capsids from directed evolution, structure-guided, and machine-learning design, the most active and contested layer.²,³,⁴,⁵

Immunogenicity and redosing claims. These cover strategies to evade pre-existing antibodies and enable redosing, a distinct and high-value layer given the field's central limitation.⁶,⁷

Transgene and expression-cassette claims. These cover promoters, regulatory elements, and the engineered transgene that control expression, a separately owned layer.

Manufacturing and purification claims. These cover producer systems, full-to-empty separation, host-cell productivity, and purification, where practical, hard-to-design-around barriers concentrate.⁸

Tissue-targeting claims. These cover receptor-guided and tissue-specific delivery, which can independently constrain a competing program.⁹

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, litigation-shaped landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant capsid, immunogenicity, cassette, and manufacturing claims regardless of terminology, attribution that resolves the many owners and license chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and disputes. Because AAV advances appear in virology and immunology literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as AAV gene therapy across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, capsid, immunogenicity, expression cassette, and manufacturing, and normalizes developer, platform-specialist, and academic owners and their license chains to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new capsids and immune-evasion strategies emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is freedom-to-operate hard for AAV gene therapy? Freedom-to-operate is hard for AAV gene therapy because a therapy is built from a capsid, an immune-evasion strategy, a transgene expression cassette, and a manufacturing process, each independently patentable and often held by different owners. The capsid layer alone is heavily engineered and contested. FTO must be assessed layer by layer across multiple estates.

Why is the capsid the key layer? The capsid is the key layer because it determines which tissues the therapy reaches and how the immune system responds, and it is where most engineering and patenting activity concentrates. Engineered capsids from directed evolution, structure-guided design, and machine learning aim to target tissues and evade immunity. That makes capsid IP the most active battleground.

What claim types create FTO risk in AAV therapy? Five claim types create FTO risk: capsid claims, immunogenicity and redosing claims, transgene and expression-cassette claims, manufacturing and purification claims, and tissue-targeting claims. Each covers a distinct layer and can be held by a different owner. The capsid and manufacturing layers are especially decisive.

Why do immunity and redosing matter so much? Immunity and redosing matter because pre-existing neutralizing antibodies exclude many patients from AAV therapy, and the immune response to a first dose generally prevents giving a second, so AAV is typically a single-dose modality. Technologies that evade pre-existing immunity or enable redosing address a central limitation. They are therefore a distinct, high-value layer.

Where is the white space in AAV gene therapy? The white space includes engineered capsids that target tissues and evade pre-existing immunity, redosing and immune-modulation technologies, manufacturing methods that raise the full-to-empty ratio, and expression-cassette designs that improve durability and specificity. Natural serotypes and liver-directed approaches are comparatively crowded. The durable, defensible value is in capsids, immune evasion, and manufacturing.

Why does AAV analysis need scientific literature? AAV analysis needs scientific literature because new capsids, immune-evasion strategies, and manufacturing advances appear in virology and immunology research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

What software helps analyze the AAV gene therapy patent landscape? Software for the AAV landscape should resolve developer, platform-specialist, and academic owners and license chains to canonical entities, cluster the capsid, immunogenicity, cassette, and manufacturing layers, search patents and scientific literature semantically, and monitor litigation and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.

Which teams need AAV patent landscape and FTO analysis? AAV patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at gene therapy and pharmaceutical companies, capsid-platform specialists, academic technology-transfer offices, and investors assessing gene therapy assets. The modular, litigation-shaped landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

Endnotes

1. Hao, Y., & Xiang, J. (2023). Biophysical characterization of the AAV capsid through the viral transduction life cycle. Journal of Genetic Engineering and Biotechnology, 21. https://doi.org/10.1186/s43141-023-00518-5
2. Fakhiri, J., Becker, S., & Grimm, D. (2022). Fantastic AAV gene therapy vectors and how to find them: random diversification, rational design and machine learning. Pathogens, 11(7), 756. https://doi.org/10.3390/pathogens11070756
3. Qi, Y., et al. (2025). Artificial intelligence-based approaches for AAV vector engineering. Advanced Science, 12. https://doi.org/10.1002/advs.202411062
4. Gao, F., et al. (2024). AAV engineering and load strategy for tropism modification, immune evasion and enhanced transgene expression. International Journal of Nanomedicine, 19. https://doi.org/10.2147/ijn.s459905
5. Fu, W., et al. (2024). Machine-learning-guided directed evolution for AAV capsid engineering. Current Pharmaceutical Design. https://doi.org/10.2174/0113816128286593240226060318
6. Barnes, C., Scheideler, O., & Schaffer, D. (2019). Engineering the AAV capsid to evade immune responses. Current Opinion in Biotechnology, 60. https://doi.org/10.1016/j.copbio.2019.01.002
7. Meumann, N., Rodríguez-Márquez, E., & Büning, H. (2020). AAV capsid engineering in liver-directed gene therapy. Expert Opinion on Biological Therapy, 21(6). https://doi.org/10.1080/14712598.2021.1865303
8. Yoon, S., Lee, D., et al. (2024). Decoding cellular mechanism of rAAV and engineering host-cell factories. Biotechnology Advances, 72. https://doi.org/10.1016/j.biotechadv.2024.108322
9. Marković, I., et al. (2025). AAV gene therapy drug development and translation of engineered ocular and neurotropic capsids. Clinical and Translational Science, 18. https://doi.org/10.1111/cts.70428
10. RegenxBio Inc. v. Sarepta Therapeutics, Inc., No. 24-1408 (Fed. Cir. Feb. 20, 2026).
11. U.S. Food and Drug Administration. Approved cellular and gene therapy products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
12. U.S. Food and Drug Administration (2017). Luxturna (voretigene neparvovec-rzyl). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna

‍

Chemical intelligence unifies three data types that chemistry R&D depends on: patents, scientific literature, and chemical structure data. A question about a compound, a reaction, or a material rarely lives in one of these alone. The relevant disclosure may sit in a patent claim, a journal paper, or a structure database, and the connection between them is where the insight is.

Most tools address only one layer. Structure databases index compounds, patent databases index filings, and literature databases index papers, and researchers toggle between them manually. That fragmentation is slow and lossy: a compound found in one system is not automatically linked to the patents that claim it or the papers that characterize it.

In 2026, AI-powered chemical intelligence closes that gap. Semantic search and a structured model of the field retrieve across patents, papers, and structures together. This article defines chemical intelligence, explains why siloed search falls short, and describes how the AI-powered approach works.

What chemical intelligence covers

Chemical intelligence spans the full evidence base for a compound or material. It includes patents and published applications, peer-reviewed papers and preprints, chemical compound and structure data, synthesis and reaction information, and regulatory and commercial signals. The defining feature is unification: the same compound is connected across every source in which it appears.

This is broader than chemical patent search. Patent search answers what has been filed; chemical intelligence answers what is known about a compound or material across the literature, the patent record, and structure data at once, which is what R&D and IP teams in chemistry, materials, and pharmaceuticals actually need.

Why siloed chemical search falls short

Siloed search forces a researcher to run the same question three times, in three systems, with three query languages, and then reconcile the results by hand. Connections are missed because no single tool sees all the evidence. A compound identified in a structure database is not tied to the patents that claim it or the papers that report its properties.

Keyword search compounds the problem. In chemistry, the same compound or reaction is described under different names, notations, and terminology, so a keyword query misses filings and papers that use unexpected language. The volume of new chemistry filings and publications continues to rise, widening the gap between what a manual, siloed search finds and what actually exists.

How AI-powered chemical intelligence works

AI-powered chemical intelligence applies semantic search across a unified corpus of patents and scientific literature, retrieving disclosures by meaning rather than exact terms. This surfaces the papers and filings that describe a compound or reaction in different language, which keyword search overlooks.

An R&D ontology links the layers. Because an ontology is a structured map of technical concepts and their relationships, it connects a compound to the patents that claim it, the papers that characterize it, and the technology domains it belongs to. That linkage is what turns three separate result sets into one coherent picture.

Agentic workflows then operate on that picture. On an AI-native platform such as Cypris, an agent can assess chemical freedom-to-operate at the claim level, assemble a competitive landscape of a chemical technology, or monitor a compound class continuously, retrieving across patents, papers, and structure data and returning cited output.

Where chemical intelligence is used

Chemical freedom-to-operate is a primary use. Chemical FTO assesses whether making, using, or selling a compound or formulation would infringe active patent claims, and it depends on retrieving claims that may describe the same chemistry in different terms. Competitive monitoring is another: teams track competitor chemical patents and pipelines continuously rather than rebuilding a picture each quarter.

Materials and formulation scouting is a third. Researchers use chemical intelligence to identify sustainable material alternatives, track new synthesis trends, and find who is active in a compound class, drawing on patents and literature together. Each of these questions is answered more completely when structure, patent, and literature evidence is unified.

Chemical intelligence in practice

Cypris is an AI-native R&D intelligence platform that unifies chemical evidence across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology, alongside chemical compound data. The ontology links compounds to the patents that claim them and the papers that characterize them, so semantic search retrieves across all of it rather than one silo.

Cypris Q, the platform's agentic layer, runs chemical FTO, landscape, and prior art workflows and returns cited output, while Agentic Monitoring tracks compound classes and competitor chemical activity continuously across patents, scientific literature, chemical compound data, and regulatory sources. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

What is a chemical intelligence platform?

A chemical intelligence platform unifies patents, scientific literature, and chemical structure data so R&D teams can search all three together rather than in separate silos. It connects a compound to the patents that claim it and the papers that characterize it, which is broader than chemical patent search alone.

What data does chemical intelligence cover?

Chemical intelligence covers patents and published applications, peer-reviewed papers and preprints, chemical compound and structure data, synthesis and reaction information, and regulatory and commercial signals. The defining feature is that the same compound is linked across every source in which it appears.

Can I search patents and chemical structures together?

Searching patents and chemical structures together requires a platform that unifies both in one corpus and links compounds to the filings that claim them. An AI-powered chemical intelligence platform does this with semantic search and an R&D ontology, so a compound and its patent coverage are connected rather than searched separately.

Is there a platform to search scientific papers and chemical structures?

A chemical intelligence platform searches scientific papers and chemical structures together by unifying literature and compound data in a single corpus. This matters because a compound's properties are often reported in papers before or alongside its appearance in patents, so searching both together gives a fuller picture.

How does AI improve chemical patent research?

AI improves chemical patent research by applying semantic search, which retrieves filings that describe the same compound or reaction in different names and notations. Combined with an R&D ontology that links compounds to their patents and papers, it surfaces evidence that keyword search across a single database misses.

What is chemical freedom-to-operate (FTO)?

Chemical freedom-to-operate assesses whether making, using, or selling a compound or formulation would infringe active patent claims. It depends on retrieving claims that may describe the same chemistry in different terms, which is why semantic search across a unified corpus is central to reliable chemical FTO.

How do R&D teams monitor competitor chemical patents?

R&D teams monitor competitor chemical patents most effectively with continuous, AI-powered monitoring that interprets new filings in the context of a compound class or technology domain. This replaces quarterly manual rebuilds and surfaces competitor chemical activity as it publishes.

Can chemical intelligence track new material synthesis trends?

Chemical intelligence can track new material synthesis trends by analyzing patents and scientific literature together and grouping activity by technical concept. This reveals where synthesis routes and material classes are developing, and which organizations are active, earlier than a patent-only view.

How does semantic search work for chemistry?

Semantic search for chemistry retrieves patents and papers by the meaning of a compound, reaction, or property rather than exact keywords. Because chemistry is described under many names and notations, semantic retrieval surfaces relevant disclosures that literal term matching overlooks.

What is the best chemical intelligence platform for R&D teams?

The best chemical intelligence platform unifies patents, scientific literature, and chemical structure data with semantic search and citable output. Cypris runs chemical intelligence on a corpus of more than 500 million patents and scientific papers organized through a proprietary R&D ontology, alongside chemical compound data, linking compounds to their patents and publications.

‍

Prior art search determines whether an invention has already been disclosed publicly, anywhere, before a given date. It underpins patentability decisions, invalidity challenges, and R&D direction. If relevant prior art exists and is missed, a patent may be granted on shaky ground, or a competitor's patent may go unchallenged when it could have been invalidated.

Prior art is not limited to patents. It includes scientific papers, conference proceedings, technical disclosures, product documentation, and other public information. This is why prior art search must span patents and scientific literature together, and why patent-only searching leaves gaps, especially in fields where research is published before it is patented.

In 2026, AI-powered prior art search applies semantic search across a unified corpus of patents and scientific literature, retrieving conceptually relevant disclosures regardless of the exact words used. This article explains how it works and how to run one.

What counts as prior art

Prior art is any public disclosure of an invention before the relevant date. It includes granted patents and published applications, but also peer-reviewed papers, preprints, conference materials, theses, standards documents, and public product information. A disclosure in any of these can defeat novelty or support an obviousness argument.

Because prior art spans formats and languages, coverage and recall are the central challenges. A search that only covers patents, or only covers one language, systematically misses disclosures that exist elsewhere. The goal of prior art search is to find the most relevant disclosures, not simply to return many documents.

Prior art search versus freedom-to-operate

Prior art search and freedom-to-operate search are often confused because they use overlapping data, but they answer different questions. Prior art search asks whether an invention is new and non-obvious, which bears on whether a patent should be granted or can be invalidated. Freedom-to-operate search asks whether commercializing a product would infringe active, in-force patent claims.

The distinction changes what each search prioritizes. Prior art search values broad recall across patents and scientific literature to establish what was already known. FTO search focuses on active claims in specific jurisdictions to assess infringement risk. Using the right search for the question is essential to reaching a defensible conclusion.

How AI-powered prior art search works

AI-powered prior art search applies semantic search, which represents the meaning of text so that conceptually similar disclosures are retrieved even when the wording differs. This directly addresses the core weakness of keyword prior art search, where a relevant paper or patent is missed because it describes the invention in different terms.

Searching patents and scientific literature in a single unified corpus is what makes AI prior art search comprehensive. Early disclosure frequently appears in the literature before it reaches granted claims, particularly in biotech, chemistry, and materials science, so a unified search surfaces disclosures that a patent-only search cannot. An R&D ontology strengthens this by interpreting queries in the context of a technology domain, improving recall for the concepts that matter.

Agentic processes extend prior art search into an end-to-end workflow. An agent can expand a query into related concepts, retrieve candidate disclosures across patents and literature, summarize each with its relevance to the claims in question, and assemble a cited prior art report, with human experts reviewing and refining the result.

How to run an AI-powered prior art search

Begin by stating the invention and its key features precisely, and set the relevant date. Convert each feature into a semantic query so that conceptually equivalent disclosures are retrieved, not only exact-term matches. Run the search across a corpus that unifies patents and scientific literature, so that non-patent disclosures are captured.

Review candidate disclosures for relevance to the specific claims or features, and separate documents that anticipate the invention from those relevant to obviousness. For an invalidity search, map each strong reference to the claim elements it discloses. Assemble the findings into a cited report, and, where the position needs to stay current, place the technology area under continuous monitoring so that newly published disclosures are assessed as they appear.

Where Cypris fits

Cypris is an AI-native R&D intelligence platform that runs prior art search with semantic search across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The unified corpus and ontology let Cypris retrieve conceptually relevant disclosures across both patents and scientific literature, rather than matching keywords in patents alone.

Cypris Q, the agentic layer, expands queries, retrieves candidate disclosures, and assembles cited output, while Agentic Monitoring keeps a technology area current as new disclosures publish. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

What is a prior art search?

A prior art search determines whether an invention has already been disclosed publicly before a given date, across patents and non-patent sources. It underpins patentability decisions and invalidity challenges, because any earlier public disclosure can defeat novelty or support an obviousness argument.

What counts as prior art?

Prior art is any public disclosure of an invention before the relevant date, including granted patents, published applications, peer-reviewed papers, preprints, conference materials, theses, standards, and public product information. A disclosure in any of these formats can be relevant to novelty or obviousness.

What is the difference between prior art search and FTO?

Prior art search asks whether an invention is new and non-obvious, while freedom-to-operate search asks whether commercializing a product would infringe active patent claims. They use overlapping data but prioritize differently: prior art search values broad recall, and FTO focuses on active claims in specific jurisdictions.

Why must prior art search include scientific literature?

Prior art search must include scientific literature because early technical disclosure often appears in papers before it reaches granted patent claims, especially in biotech, chemistry, and materials science. A patent-only search systematically misses these non-patent disclosures.

How does AI improve prior art search?

AI improves prior art search by applying semantic search, which retrieves conceptually relevant disclosures even when the wording differs from the query. This addresses the main weakness of keyword prior art search, where relevant references are missed because they use unexpected terminology.

What is semantic prior art search?

Semantic prior art search represents the meaning of text so that conceptually similar disclosures are retrieved regardless of exact wording. It surfaces relevant patents and papers that keyword search overlooks, improving recall across a unified corpus of patents and scientific literature.

Can prior art search be automated with agents?

Prior art search can be automated with agentic processes that expand a query into related concepts, retrieve candidate disclosures across patents and literature, summarize each, and assemble a cited report. Human experts review and refine the output, while agents handle retrieval and synthesis at scale.

How do you run an invalidity prior art search?

An invalidity prior art search maps strong references to the specific claim elements they disclose, establishing what was already known before the relevant date. Semantic search across a unified corpus improves the chance of finding the anticipating or obviousness references that keyword search misses.

What data coverage does an effective prior art search need?

An effective prior art search needs broad coverage across patents and scientific literature in multiple languages, because prior art spans formats and jurisdictions. A corpus of more than 500 million patents and scientific papers organized through an R&D ontology supports the recall that prior art search requires.

What is the best software for prior art search?

The best prior art search software combines a unified corpus of patents and scientific literature with semantic search and citable output. Cypris runs prior art search across more than 500 million patents and scientific papers organized through a proprietary R&D ontology, retrieving conceptually relevant disclosures and assembling cited results.

‍